Risks Relating to R&D Results and the Market Suitability of New Products
First written in FY2016. 11 of 13 entries say "Restated". Latest entry: FY2022.
1 other company's latest entry also says "Mitigated".
- FY2022MitigatedAnnual report
「Strengthening the selection of research and development themes based on market needs; monitoring progress through the PDCA cycle; accelerating development through collaboration with external organisations and other forms of open innovation; and promoting strategic M&A.」
Measures addressing the risk associated with new product development capabilities have been specified, including theme selection, the PDCA cycle, collaboration with external organisations, and strategic M&A. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
No material changes are reported in the risks relating to research and development results and the marketability of new products. - FY2020-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
No material changes are reported in the risks relating to research and development results and the marketability of new products. - FY2020-Q1RestatedAnnual report
「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
No material changes are reported in the risks relating to research and development results and the marketability of new products. - FY2019-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
No material changes are reported in the risks relating to research and development results and the marketability of new products. - FY2019-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
No material changes are reported in the risks relating to research and development results and the marketability of new products. - FY2019-Q1RestatedAnnual report
「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
No material changes are reported in the risks relating to research and development results and the marketability of new products. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
No material changes are reported in the risks relating to research and development results and the marketability of new products. - FY2018-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
No material changes are reported in the risks relating to research and development results and the marketability of new products. - FY2018-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
No material changes are reported in the risks relating to research and development results and the marketability of new products. - FY2017-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
No material changes are reported in the risks relating to research and development results and the marketability of new products. - FY2017-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
No material changes are reported in the risks relating to research and development results and the marketability of new products. - FY2016First statedAnnual report
「Research results do not necessarily lead to the establishment of new technologies or manufacturing processes, and extended research periods may increase development costs and result in lost sales opportunities.」
Uncertainties relating to research results, new technologies and manufacturing processes, development periods, and intellectual property protection are disclosed.